

Allergy Testing (CMS L34313)

CPT 86003

Medicare Local Coverage Determination (LCD)

- CMS LCD website: [LCD - Allergy Testing \(L34313\)](#)
- Provider Responsibility: Ordering provider is responsible to ensure appropriate diagnostic coding for a test.
- ABN Reminder: If you are ordering this test for diagnostic reasons that are not covered under Medicare policy, an Advanced Beneficiary Notice (ABN) form is required.

COVERAGE GUIDANCE

Coverage Indications, Limitations, and/or Medical Necessity

Allergy refers to conditions in which immune responses to environmental antigens cause tissue inflammation and organ dysfunction. Allergy testing is performed to determine immunologic sensitivity or reaction to antigens for the purpose of identifying the cause of the allergic state. This policy addresses immediate (IgE-mediated) hypersensitivity and delayed (cell mediated) hypersensitivity. In vivo allergy sensitivity testing correlates the performance and evaluation of selective cutaneous and mucous membrane tests with the patient's history, physical examination, and other observations.

Immediate hypersensitivity may also be tested in vitro by measurement of allergen-specific serum IgE. Under certain limited conditions, this is covered by Medicare Part B. Immediate hypersensitivity skin testing is important in the diagnosis of IgE mediated inhalant, food, venom; and penicillin allergies, delayed hypersensitivity testing is more often helpful in the diagnosis of contact dermatitis and the clinical evaluation of cell-mediated immunity.

INDICATIONS

Allergy testing is allowed when it has proven efficacy as demonstrated through scientifically valid peer reviewed published medical studies.

- A complete medical and immunologic history and appropriate physical examination must be done prior to performing diagnostic testing.
- The testing must be performed based on this history and a physical exam, which documents that the antigen being used for testing exists with a reasonable probability of exposure in the patient's environment.
- It would not be expected that all patients would receive the same tests or the same number of sensitivity tests. The number of tests performed must be judicious and related to the history, physical findings, and clinical judgment specific to each individual.

General Information

In vivo immunologic tests have been shown to be reliable and valid diagnostic tools and include skin tests with standardized allergenic extracts by prick, puncture, and intradermal techniques, skin end-point titration, and patch testing.

- **Percutaneous Testing** remains the test of choice in most clinical situations where immediate hypersensitivity reactions are suspected. Percutaneous tests require medical supervision, since there is a small but significant risk of anaphylaxis. Overall, skin testing is quick, safe, and cost-effective.
- **Intracutaneous/Intradermal Tests** are usually performed when increased sensitivity is the main goal such as when percutaneous tests are negative and there is a strong suspicion of allergen sensitivity. The usual testing program may include 2 concentrations of an extract: a weaker concentration and a stronger concentration. It would not be expected that 3 or more concentrations of one extract would be medically necessary.

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> →

Allergy Testing (CMS L34313)

CPT 86003

General Information (continued)

- **Skin End Point Titration Testing** analyzes the highest dilution of a substance that produces a reaction, and may be used to determine the starting dose(s) of allergen immunotherapy.
- **Delayed Hypersensitivity Skin Testing** has been commonly used in three ways: anergy testing, testing for infection with intracellular pathogens, and testing for sensitivity to contact allergens. Accurate testing for contact allergy requires careful attention to technique, and limitation of testing to the specific allergens known to be associated with a contact reaction.
- **Photo Testing** is skin irradiation with a specific range of ultraviolet light. Photo tests are performed for the evaluation of photosensitivity disorders.
- **Patch Testing** is indicated to evaluate a nonspecific dermatitis, allergic contact dermatitis, pruritus, and other dermatitis to determine the causative antigen.
- **Photo Patch Testing** uses two patches, with one of them being irradiated with ultraviolet light half way through the occlusive period. It is indicated to evaluate unique allergies resulting from light exposure.
- **Ophthalmic Mucous Membrane Tests and Direct Nasal Mucous Membrane Tests** are rarely indicated. They are allowed when skin testing cannot test allergens.
- **Inhalation Bronchial Challenge Testing** involves the inhalation of agents that can trigger respiratory responses. The agents include drugs that cause airway constriction, antigens and chemical sensitizers usually related to occupational breathing problems. Pulmonary function studies are not included in the bronchial challenge test. Generally three measures of each determination (e.g., spirometry, prolonged post exposure evaluation of bronchospasm) are performed. The best of the three is accepted and represents one unit of service. A unit is defined as each set of three measurements.
- **Ingestion Challenge Test** involves the administration of sequentially or incrementally larger doses of the test item. The test items may include food or antibiotics. The service is allowed once per patient encounter, regardless of the number of items tested, and includes evaluation of the patient's response to the test items.

LIMITATIONS

- **Ingestion challenge food testing** performed by the patient in the home, and not in the office setting, will not be covered.
- **Provocative** testing will be denied as not medically necessary.
- **Quantitative or semi-quantitative in vitro allergen specific IgE testing** is covered under conditions where skin testing is not possible or is not reliable. In vitro testing is covered as a SUBSTITUTE for skin testing; it is usually not necessary in addition to skin testing. The number of tests done, frequency of retesting and other coverage issues, are the same as for skin testing. The indications for using in vitro testing instead of in vivo methods must be documented with the claim.
- **Qualitative multiallergen screens for allergen specific IgE** have insufficient literature to support clear-cut clinical utility and will be denied as not medically necessary.

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

LIMITATIONS (continued)

Examples of indications for in vitro testing include the following:

- Patients with severe dermatographism, ichthyosis or generalized eczema;
- Patients at increased risk for anaphylactic response to skin testing based on clinical history (e.g., when an unusual allergen is not available as a licensed skin test extract);
- Patients unable to discontinue long-acting antihistamines, tricyclic antidepressants, or medications that may put the patient at undue risk if they are discontinued long enough to perform skin tests;
- Patients with mental or physical impairments, who are uncooperative; or
- Evaluation of cross-reactivity between insect venoms.

The following are noncovered antigens: newsprint, tobacco smoke, dandelion, orris root, phenol, alcohol, sugar, yeast, grain mill dust, soybean dust (except when the patient has a known exposure to soybean dust such as a food processing plant), honeysuckle, fiberglass, green tea, or chalk.

Associated Information

Documentation Requirements

It is expected that supportive documentation evidencing the condition and treatment will be documented in the medical record and be available to the Contractor upon request.

Documentation, such as ICD-10-CM codes, supporting the medical necessity of the service must be submitted with each claim. Claims submitted without such evidence will be denied as not medically reasonable and necessary.

Utilization Guidelines

The evaluation of an inhalant may require up to 90 prick-puncture tests followed by up to 40 intracutaneous tests which are usually performed when prick/puncture tests are negative. Sometimes 60 intracutaneous tests performed via multi test, in lieu of prick puncture, may be appropriate for selected patients (for example young children, older adults and needle phobic individuals.)

The number of percutaneous tests performed for the evaluation of food sensitivity may require up to 40 tests.

The total number of tests, i.e. prick or intracutaneous, should not exceed generally accepted standards of testing set forth by professional associations. Exceeding these parameters may be justified if preliminary testing failed and immunotherapy failed to control symptoms.

In California, for percutaneous allergy testing, among patients treated by Allergists, over half required fewer than 100 tests. The great majority required less than 120-130 tests, and only 5% required more than 200 tests. Some of the high-test group includes repeat testing necessitated by unsatisfactory response to clinical treatment and a clinical need for further investigation. For intracutaneous (intra-dermal) allergy testing, among patients treated by Allergists, over half required only 12 tests, and only 5% required 70 or more tests. High-utilization testing may be selected for medical review when inconsistent with clinical practice norms.

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Group 1 (402 Codes): The following list of ICD-10-CM Codes will be covered for CPT Code 86003:

Code	Description
H10.411	Chronic giant papillary conjunctivitis, right eye
H10.412	Chronic giant papillary conjunctivitis, left eye
H10.413	Chronic giant papillary conjunctivitis, bilateral
H10.45	Other chronic allergic conjunctivitis
H65.111	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), right ear
H65.112	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), left ear
H65.113	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), bilateral
H65.114	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, right ear
H65.115	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, left ear
H65.116	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, bilateral
H65.194	Other acute nonsuppurative otitis media, recurrent, right ear
H65.195	Other acute nonsuppurative otitis media, recurrent, left ear
H65.196	Other acute nonsuppurative otitis media, recurrent, bilateral
H65.21	Chronic serous otitis media, right ear
H65.22	Chronic serous otitis media, left ear
H65.23	Chronic serous otitis media, bilateral
H65.411	Chronic allergic otitis media, right ear
H65.412	Chronic allergic otitis media, left ear
H65.413	Chronic allergic otitis media, bilateral
H65.491	Other chronic nonsuppurative otitis media, right ear
H65.492	Other chronic nonsuppurative otitis media, left ear
H65.493	Other chronic nonsuppurative otitis media, bilateral
H68.021	Chronic Eustachian salpingitis, right ear
H68.022	Chronic Eustachian salpingitis, left ear
H68.023	Chronic Eustachian salpingitis, bilateral
H69.81	Other specified disorders of Eustachian tube, right ear
H69.82	Other specified disorders of Eustachian tube, left ear
H69.83	Other specified disorders of Eustachian tube, bilateral
J20.8	Acute bronchitis due to other specified organisms
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J31.0	Chronic rhinitis
J32.0	Chronic maxillary sinusitis

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
J32.1	Chronic frontal sinusitis
J32.2	Chronic ethmoidal sinusitis
J32.3	Chronic sphenoidal sinusitis
J32.4	Chronic pansinusitis
J32.8	Other chronic sinusitis
J32.9	Chronic sinusitis, unspecified
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J34.1	Cyst and mucocele of nose and nasal sinus
J34.81	Nasal mucositis (ulcerative)
J35.01	Chronic tonsillitis
J35.02	Chronic adenoiditis
J35.03	Chronic tonsillitis and adenoiditis
J35.1	Hypertrophy of tonsils
J35.2	Hypertrophy of adenoids
J35.3	Hypertrophy of tonsils with hypertrophy of adenoids
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.83	Infantile (acute) (chronic) eczema
L20.84	Intrinsic (allergic) eczema

REMINDER: The ordering provider is solely responsibility for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
L20.89	Other atopic dermatitis
L20.9	Atopic dermatitis, unspecified
L27.0	Generalized skin eruption due to drugs and medicaments taken internally
L27.1	Localized skin eruption due to drugs and medicaments taken internally
L27.2	Dermatitis due to ingested food
L27.8	Dermatitis due to other substances taken internally
L27.9	Dermatitis due to unspecified substance taken internally
L30.0	Nummular dermatitis
L30.2	Cutaneous autosensitization
L30.8	Other specified dermatitis
L50.0	Allergic urticaria
L50.1	Idiopathic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified
R06.00	Dyspnea, unspecified
R06.02	Shortness of breath
R06.09	Other forms of dyspnea
R06.2	Wheezing
R06.9	Unspecified abnormalities of breathing
R09.81	Nasal congestion
R21	Rash and other nonspecific skin eruption
R43.0	Anosmia
R43.1	Parosmia
R43.2	Parageusia
R43.8	Other disturbances of smell and taste
R43.9	Unspecified disturbances of smell and taste
T36.0X5A	Adverse effect of penicillins, initial encounter
T36.0X5S	Adverse effect of penicillins, sequela
T36.1X5A	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.1X5S	Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
T36.2X5A	Adverse effect of chloramphenicol group, initial encounter
T36.2X5S	Adverse effect of chloramphenicol group, sequela
T36.3X5A	Adverse effect of macrolides, initial encounter
T36.3X5S	Adverse effect of macrolides, sequela
T36.4X5A	Adverse effect of tetracyclines, initial encounter
T36.4X5S	Adverse effect of tetracyclines, sequela
T36.5X5A	Adverse effect of aminoglycosides, initial encounter
T36.5X5S	Adverse effect of aminoglycosides, sequela
T36.6X5A	Adverse effect of rifampicins, initial encounter

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T36.6X5S	Adverse effect of rifampicins, sequela
T36.7X5A	Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.7X5S	Adverse effect of antifungal antibiotics, systemically used, sequela
T36.8X5A	Adverse effect of other systemic antibiotics, initial encounter
T36.8X5S	Adverse effect of other systemic antibiotics, sequela
T37.0X5A	Adverse effect of sulfonamides, initial encounter
T37.0X5S	Adverse effect of sulfonamides, sequela
T37.1X5A	Adverse effect of antimycobacterial drugs, initial encounter
T37.1X5S	Adverse effect of antimycobacterial drugs, sequela
T37.2X5A	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.2X5S	Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
T37.3X5A	Adverse effect of other antiprotozoal drugs, initial encounter
T37.3X5S	Adverse effect of other antiprotozoal drugs, sequela
T37.4X5A	Adverse effect of anthelmintics, initial encounter
T37.4X5S	Adverse effect of anthelmintics, sequela
T37.5X5A	Adverse effect of antiviral drugs, initial encounter
T38.0X5A	Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.0X5S	Adverse effect of glucocorticoids and synthetic analogues, sequela
T38.1X5A	Adverse effect of thyroid hormones and substitutes, initial encounter
T38.1X5S	Adverse effect of thyroid hormones and substitutes, sequela
T38.2X5A	Adverse effect of antithyroid drugs, initial encounter
T38.2X5S	Adverse effect of antithyroid drugs, sequela
T38.3X5A	Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
T38.3X5S	Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
T38.4X5A	Adverse effect of oral contraceptives, initial encounter
T38.4X5S	Adverse effect of oral contraceptives, sequela
T38.5X5A	Adverse effect of other estrogens and progestogens, initial encounter
T38.5X5S	Adverse effect of other estrogens and progestogens, sequela
T38.6X5A	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.6X5S	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
T38.7X5A	Adverse effect of androgens and anabolic congeners, initial encounter
T38.7X5S	Adverse effect of androgens and anabolic congeners, sequela
T38.815A	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.815S	Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
T38.895A	Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.895S	Adverse effect of other hormones and synthetic substitutes, sequela
T38.995A	Adverse effect of other hormone antagonists, initial encounter
T38.995S	Adverse effect of other hormone antagonists, sequela
T39.015A	Adverse effect of aspirin, initial encounter
T39.015S	Adverse effect of aspirin, sequela

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T39.095A	Adverse effect of salicylates, initial encounter
T39.095S	Adverse effect of salicylates, sequela
T39.1X5A	Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.1X5S	Adverse effect of 4-Aminophenol derivatives, sequela
T39.2X5A	Adverse effect of pyrazolone derivatives, initial encounter
T39.2X5S	Adverse effect of pyrazolone derivatives, sequela
T39.315A	Adverse effect of propionic acid derivatives, initial encounter
T39.315S	Adverse effect of propionic acid derivatives, sequela
T39.395A	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.395S	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T39.4X5A	Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.4X5S	Adverse effect of antirheumatics, not elsewhere classified, sequela
T39.8X5A	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.8X5S	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
T40.0X5A	Adverse effect of opium, initial encounter
T40.0X5S	Adverse effect of opium, sequela
T40.2X5A	Adverse effect of other opioids, initial encounter
T40.2X5S	Adverse effect of other opioids, sequela
T40.3X5A	Adverse effect of methadone, initial encounter
T40.3X5S	Adverse effect of methadone, sequela
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter
T40.415S	Adverse effect of fentanyl or fentanyl analogs, sequela
T40.425A	Adverse effect of tramadol, initial encounter
T40.425S	Adverse effect of tramadol, sequela
T40.495A	Adverse effect of other synthetic narcotics, initial encounter
T40.495S	Adverse effect of other synthetic narcotics, sequela
T40.5X5A	Adverse effect of cocaine, initial encounter
T40.5X5S	Adverse effect of cocaine, sequela
T40.695A	Adverse effect of other narcotics, initial encounter
T40.695S	Adverse effect of other narcotics, sequela
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T40.995S	Adverse effect of other psychodysleptics [hallucinogens], sequela
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.0X5S	Adverse effect of inhaled anesthetics, sequela
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.1X5S	Adverse effect of intravenous anesthetics, sequela
T41.295A	Adverse effect of other general anesthetics, initial encounter
T41.295S	Adverse effect of other general anesthetics, sequela
T41.3X5A	Adverse effect of local anesthetics, initial encounter
T41.3X5S	Adverse effect of local anesthetics, sequela

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T41.5X5A	Adverse effect of therapeutic gases, initial encounter
T41.5X5S	Adverse effect of therapeutic gases, sequela
T42.0X5A	Adverse effect of hydantoin derivatives, initial encounter
T42.0X5S	Adverse effect of hydantoin derivatives, sequela
T42.1X5A	Adverse effect of iminostilbenes, initial encounter
T42.1X5S	Adverse effect of iminostilbenes, sequela
T42.2X5A	Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.2X5S	Adverse effect of succinimides and oxazolidinediones, sequela
T42.3X5A	Adverse effect of barbiturates, initial encounter
T42.4X5A	Adverse effect of benzodiazepines, initial encounter
T42.4X5S	Adverse effect of benzodiazepines, sequela
T42.5X5A	Adverse effect of mixed antiepileptics, initial encounter
T42.5X5S	Adverse effect of mixed antiepileptics, sequela
T42.6X5A	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.6X5S	Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
T42.8X5A	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T42.8X5S	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
T43.015A	Adverse effect of tricyclic antidepressants, initial encounter
T43.015S	Adverse effect of tricyclic antidepressants, sequela
T43.025A	Adverse effect of tetracyclic antidepressants, initial encounter
T43.025S	Adverse effect of tetracyclic antidepressants, sequela
T43.1X5A	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.1X5S	Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
T43.215A	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.215S	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
T43.225A	Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.225S	Adverse effect of selective serotonin reuptake inhibitors, sequela
T43.295A	Adverse effect of other antidepressants, initial encounter
T43.295S	Adverse effect of other antidepressants, sequela
T43.3X5A	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.3X5S	Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
T43.4X5A	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.4X5S	Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
T43.595A	Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.595S	Adverse effect of other antipsychotics and neuroleptics, sequela
T43.615A	Adverse effect of caffeine, initial encounter
T43.615S	Adverse effect of caffeine, sequela
T43.625A	Adverse effect of amphetamines, initial encounter
T43.625S	Adverse effect of amphetamines, sequela
T43.635A	Adverse effect of methylphenidate, initial encounter

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T43.635S	Adverse effect of methylphenidate, sequela
T43.655A	Adverse effect of methamphetamines, initial encounter
T43.655D	Adverse effect of methamphetamines, subsequent encounter
T43.655S	Adverse effect of methamphetamines, sequela
T43.695A	Adverse effect of other psychostimulants, initial encounter
T43.695S	Adverse effect of other psychostimulants, sequela
T43.8X5A	Adverse effect of other psychotropic drugs, initial encounter
T43.8X5S	Adverse effect of other psychotropic drugs, sequela
T44.0X5A	Adverse effect of anticholinesterase agents, initial encounter
T44.0X5S	Adverse effect of anticholinesterase agents, sequela
T44.1X5A	Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.1X5S	Adverse effect of other parasympathomimetics [cholinergics], sequela
T44.2X5A	Adverse effect of ganglionic blocking drugs, initial encounter
T44.2X5S	Adverse effect of ganglionic blocking drugs, sequela
T44.3X5A	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X5S	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.4X5A	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X5S	Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.5X5A	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X5S	Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.6X5A	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.6X5S	Adverse effect of alpha-adrenoreceptor antagonists, sequela
T44.7X5A	Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5S	Adverse effect of beta-adrenoreceptor antagonists, sequela
T44.8X5A	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X5S	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.995A	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T44.995S	Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
T45.0X5A	Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5S	Adverse effect of antiallergic and antiemetic drugs, sequela
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.2X5A	Adverse effect of vitamins, initial encounter
T45.2X5S	Adverse effect of vitamins, sequela
T45.3X5A	Adverse effect of enzymes, initial encounter
T45.3X5S	Adverse effect of enzymes, sequela
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.4X5S	Adverse effect of iron and its compounds, sequela
T45.515A	Adverse effect of anticoagulants, initial encounter
T45.515S	Adverse effect of anticoagulants, sequela

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T45.525A	Adverse effect of antithrombotic drugs, initial encounter
T45.525S	Adverse effect of antithrombotic drugs, sequela
T45.615A	Adverse effect of thrombolytic drugs, initial encounter
T45.615S	Adverse effect of thrombolytic drugs, sequela
T45.625A	Adverse effect of hemostatic drug, initial encounter
T45.625S	Adverse effect of hemostatic drug, sequela
T45.695A	Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.695S	Adverse effect of other fibrinolysis-affecting drugs, sequela
T45.7X5A	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.7X5S	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
T45.8X5A	Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.8X5S	Adverse effect of other primarily systemic and hematological agents, sequela
T46.0X5A	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.0X5S	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.1X5A	Adverse effect of calcium-channel blockers, initial encounter
T46.1X5S	Adverse effect of calcium-channel blockers, sequela
T46.2X5A	Adverse effect of other antidysrhythmic drugs, initial encounter
T46.2X5S	Adverse effect of other antidysrhythmic drugs, sequela
T46.3X5A	Adverse effect of coronary vasodilators, initial encounter
T46.3X5S	Adverse effect of coronary vasodilators, sequela
T46.4X5A	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.4X5S	Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
T46.5X5A	Adverse effect of other antihypertensive drugs, initial encounter
T46.5X5S	Adverse effect of other antihypertensive drugs, sequela
T46.6X5A	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.6X5S	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.7X5A	Adverse effect of peripheral vasodilators, initial encounter
T46.7X5S	Adverse effect of peripheral vasodilators, sequela
T46.8X5A	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.8X5S	Adverse effect of antivaricose drugs, including sclerosing agents, sequela
T46.995A	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T46.995S	Adverse effect of other agents primarily affecting the cardiovascular system, sequela
T47.0X5A	Adverse effect of histamine H2-receptor blockers, initial encounter
T47.0X5S	Adverse effect of histamine H2-receptor blockers, sequela
T47.1X5A	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.1X5S	Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
T47.2X5A	Adverse effect of stimulant laxatives, initial encounter
T47.2X5S	Adverse effect of stimulant laxatives, sequela
T47.3X5A	Adverse effect of saline and osmotic laxatives, initial encounter
T47.3X5S	Adverse effect of saline and osmotic laxatives, sequela

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T47.4X5A	Adverse effect of other laxatives, initial encounter
T47.4X5S	Adverse effect of other laxatives, sequela
T47.5X5A	Adverse effect of digestants, initial encounter
T47.5X5S	Adverse effect of digestants, sequela
T47.6X5A	Adverse effect of antidiarrheal drugs, initial encounter
T47.6X5S	Adverse effect of antidiarrheal drugs, sequela
T47.7X5A	Adverse effect of emetics, initial encounter
T47.7X5S	Adverse effect of emetics, sequela
T47.8X5A	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.8X5S	Adverse effect of other agents primarily affecting gastrointestinal system, sequela
T48.0X5A	Adverse effect of oxytocic drugs, initial encounter
T48.0X5S	Adverse effect of oxytocic drugs, sequela
T48.1X5A	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.1X5S	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.295A	Adverse effect of other drugs acting on muscles, initial encounter
T48.295S	Adverse effect of other drugs acting on muscles, sequela
T48.3X5A	Adverse effect of antitussives, initial encounter
T48.3X5S	Adverse effect of antitussives, sequela
T48.4X5A	Adverse effect of expectorants, initial encounter
T48.4X5S	Adverse effect of expectorants, sequela
T48.5X5A	Adverse effect of other anti-common-cold drugs, initial encounter
T48.5X5S	Adverse effect of other anti-common-cold drugs, sequela
T48.6X5A	Adverse effect of antiasthmatics, initial encounter
T48.6X5S	Adverse effect of antiasthmatics, sequela
T48.995A	Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T48.995S	Adverse effect of other agents primarily acting on the respiratory system, sequela
T49.0X5A	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.0X5S	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
T49.1X5A	Adverse effect of antipruritics, initial encounter
T49.1X5S	Adverse effect of antipruritics, sequela
T49.2X5A	Adverse effect of local astringents and local detergents, initial encounter
T49.2X5S	Adverse effect of local astringents and local detergents, sequela
T49.3X5A	Adverse effect of emollients, demulcents and protectants, initial encounter
T49.3X5S	Adverse effect of emollients, demulcents and protectants, sequela
T49.4X5A	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.4X5S	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
T49.5X5A	Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.5X5S	Adverse effect of ophthalmological drugs and preparations, sequela
T49.6X5A	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.6X5S	Adverse effect of otorhinolaryngological drugs and preparations, sequela

REMINDER: The ordering provider is solely responsibility for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T49.7X5A	Adverse effect of dental drugs, topically applied, initial encounter
T49.7X5S	Adverse effect of dental drugs, topically applied, sequela
T49.8X5A	Adverse effect of other topical agents, initial encounter
T49.8X5S	Adverse effect of other topical agents, sequela
T50.0X5A	Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.0X5S	Adverse effect of mineralocorticoids and their antagonists, sequela
T50.1X5A	Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.1X5S	Adverse effect of loop [high-ceiling] diuretics, sequela
T50.2X5A	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.2X5S	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
T50.3X5A	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.3X5S	Adverse effect of electrolytic, caloric and water-balance agents, sequela
T50.4X5A	Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.4X5S	Adverse effect of drugs affecting uric acid metabolism, sequela
T50.5X5A	Adverse effect of appetite depressants, initial encounter
T50.5X5S	Adverse effect of appetite depressants, sequela
T50.6X5A	Adverse effect of antidotes and chelating agents, initial encounter
T50.6X5S	Adverse effect of antidotes and chelating agents, sequela
T50.7X5A	Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.7X5S	Adverse effect of analeptics and opioid receptor antagonists, sequela
T50.8X5A	Adverse effect of diagnostic agents, initial encounter
T50.8X5S	Adverse effect of diagnostic agents, sequela
T50.A15A	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A15S	Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
T50.A25A	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A25S	Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
T50.A95A	Adverse effect of other bacterial vaccines, initial encounter
T50.A95S	Adverse effect of other bacterial vaccines, sequela
T50.B15A	Adverse effect of smallpox vaccines, initial encounter
T50.B15S	Adverse effect of smallpox vaccines, sequela
T50.B95A	Adverse effect of other viral vaccines, initial encounter
T50.B95S	Adverse effect of other viral vaccines, sequela
T50.Z15A	Adverse effect of immunoglobulin, initial encounter
T50.Z15S	Adverse effect of immunoglobulin, sequela
T50.Z95A	Adverse effect of other vaccines and biological substances, initial encounter
T50.Z95S	Adverse effect of other vaccines and biological substances, sequela
T50.915A	Adverse effect of multiple unspecified drugs, medicaments and biological substances, initial encounter
T50.915D	Adverse effect of multiple unspecified drugs, medicaments and biological substances, subsequent encounter
T50.915S	Adverse effect of multiple unspecified drugs, medicaments and biological substances, sequela
T50.995A	Adverse effect of other drugs, medicaments and biological substances, initial encounter

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒

Allergy Testing (CMS L34313)

CPT 86003

Code	Description
T50.995S	Adverse effect of other drugs, medicaments and biological substances, sequela
T78.40XA	Allergy, unspecified, initial encounter
T78.40XD	Allergy, unspecified, subsequent encounter
T78.40XS	Allergy, unspecified, sequela

REMINDER: The ordering provider is solely responsible for assigning diagnosis (codes). PDL does not, through this Reference Guide or otherwise, recommend any particular diagnosis codes. PDL will submit to Medicare only the diagnosis (codes) provided to PDL by the ordering provider and/or his/her authorized staff. Complete policy and full list of medical necessity codes, refer to CMS website reference: <https://www.cms.gov/> ⇒